ABVC BioPharma Inc ABVC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.31
- Day Range
- $1.19–1.33
- 52-Week Range
- $0.88–5.48
- Bid/Ask
- $1.04 / $1.30
- Shares Outstanding
- 26.00M
- Market Cap
- $30.94M
- Volume/Avg
- 77,028 / 108,920
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 37.41
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 19
- Website
- https://www.abvcpharma.com
Valuation
|
Metric
|
ABVC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.04 |
Price/Sales | 37.41 |
Price/Cash Flow | — |
Price/Earnings
ABVC
Financial Strength
|
Metric
|
ABVC
|
|---|---|
Quick Ratio | 0.07 |
Current Ratio | 0.12 |
Interest Coverage | −37.18 |
Quick Ratio
ABVC
Profitability
|
Metric
|
ABVC
|
|---|---|
Return on Assets (Normalized) | −24.88% |
Return on Equity (Normalized) | −49.96% |
Return on Invested Capital (Normalized) | −32.85% |
Return on Assets
ABVC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Jglhfqfp | Ztxlxl | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Cxjflcdt | Lqgrw | $64B | |||
| argenx SE ADR
ARGX
| Fvwgjnd | Mdc | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Bfpzyqv | Qclwmnz | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Rghzcknzc | Wjkrg | $24B | |||
| BioNTech SE ADR
BNTX
| Nstpcpwz | Wbvxq | $23B | |||
| Incyte Corp
INCY
| Nkjwzrlg | Rlbt | $22B | |||
| Moderna Inc
MRNA
| Jfqbhmqtc | Kxch | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Krvfffb | Fnvzl | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Kkzywbtb | Dhqxk | $13B |
United States